Cargando…
SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A
SET is known as a potent PP2A inhibitor, however, its oncogenic role including its tumorigenic potential and involvement in the development of chemoresistance in non-small cell lung cancer (NSCLC) has not yet been fully discussed. In present study, we investigated the oncogenic role of SET by SET-kn...
Autores principales: | Hung, Man-Hsin, Wang, Cheng-Yi, Chen, Yen-Lin, Chu, Pei-Yi, Hsiao, Yung-Jen, Tai, Wei-Tien, Chao, Ting-Ting, Yu, Hui-Chuan, Shiau, Chung-Wai, Chen, Kuen-Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808023/ https://www.ncbi.nlm.nih.gov/pubmed/26575017 |
Ejemplares similares
-
SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma
por: Tai, Wei-Tien, et al.
Publicado: (2016) -
Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A–dependent phospho-Akt inactivation in estrogen receptor–negative human breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2014) -
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
por: Su, Tung-Hung, et al.
Publicado: (2017) -
Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway
por: Tsai, Kuen-Jang, et al.
Publicado: (2021) -
Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner
por: Hsieh, Feng‐Shu, et al.
Publicado: (2017)